B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood St Thomas’ Hospital / King’s College London On behalf of the BCIS-1 Investigators.

Slides:



Advertisements
Similar presentations
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood Kings College London/ St Thomas Hospital Steering Committee: Divaka Perera,
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
VA NQWISH Veterans Affairs Non-Q Wave Infarction Strategies In-Hopsital Trial.
FFR vs Angiography for Multivessel Evaluation
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Impella Technology Elective Support Clinical Evidence and Investigations.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
Coronary Artery Revascularisation
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
AB 1/03 Non-Coronary Intervention Circulatory Support Advanced Angioplasty 2003 Andreas Baumbach Bristol Royal Infirmary.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
IABP用于高危PCI有价值吗? Is IABP Valuable for High-Risk PCI?
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
AntiThrombotic Therapy in the Cath Lab: Preliminary Results from the NICE Trials Cindy L. Grines, M.D. William Beaumont Hospital Royal Oak, Michigan Cindy.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Debate: Prophylactic Support Increases Risk With Little Benefit
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Improving Outcomes in Cardiogenic Shock
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
Presented by Dr. Leif Thuesen
European Heart Association Journal 2007 April
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Impact of Platelet Reactivity Following Clopidogrel Administration
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Presentation transcript:

B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood St Thomas’ Hospital / King’s College London On behalf of the BCIS-1 Investigators Steering Committee: Divaka Perera, Rod Stables, Jean Booth, Martyn Thomas

1 Potential conflicts of interest Potential conflicts of interest Speaker’s name: Simon Redwood √ I do not have any potential conflict of interest This trial was supported by unrestricted grants from: Datascope/ Maquet Eli Lilly Cordis

Trial Organization Steering Committee Divaka Perera, Rod Stables, Martyn Thomas, Jean Booth, Simon Redwood Clinical Events Committee James Cotton, Nick Curzen, Adam de Belder, David Roberts Data Monitoring and Safety Committee Peter Ludman (Chair), Gerald Stansby, Chris Palmer Clinical Trials and Evaluation Unit Jean Booth, Fiona Nugara, Marcus Flather, Charlotte Gillam, Michael Roughton, Winston Banya

Elective vs provisional IABP in high-risk PCI 133 pts EF <30, elective PCI Elective IABP, 61 pts. Jeopardy Score Provisional IABP, 72 pts. Jeopardy Score (p=0.008) Correlates of MACE Odds Ratio Elective IABP0.11 Jeopardy Score5.37 % Briguori et al, AHJ 2003;145:700-7 P = 0.01 P = 0.29

Objectives: To compare the efficacy and safety of elective Intra-Aortic Balloon Pump (IABP) insertion prior to high-risk PCI vs. conventional treatment (with no planned IABP use) Structure: Prospective, open, randomized trial Prospective, open, randomized trial 17 UK centres 17 UK centres n=300 (150 in each arm) n=300 (150 in each arm) Sample Size = 274 pts (predicted MACCE 5% vs. 15%, β=80%, α= 5%) B alloon-pump assisted C oronary I ntervention S tudy

LVEF < 30% Jeopardy Score ≥ 8 Randomize 6 month follow-up Elective IABP Insertion No Planned IABP PCI Remove IABP 4-24 hrs after PCI Hospital Follow-up To discharge or 28 days

Primary Outcome Measure Major Adverse Cardiovascular or Cerebral Events (MACCE) at hospital discharge or 28 days (whichever is sooner), including All-Cause Death All-Cause Death Acute MI Acute MI Further revascularization by PCI or CABG Further revascularization by PCI or CABG CVA CVA BCIS-1 Perera et al AHJ 2009; in press

Secondary Outcome Measures Six month mortality Six month mortality Procedural complications Procedural complications Prolonged hypotension ORProlonged hypotension OR VT/VF requiring cardioversion ORVT/VF requiring cardioversion OR Cardiac arrest requiring CPR/ventilationCardiac arrest requiring CPR/ventilation Bleeding complications Bleeding complications Vascular complications Vascular complications Procedural success Procedural success Duration of hospital stay Duration of hospital stay

Study Definitions Myocardial Infarction 1. < 72 hrs post PCI, baseline CKMB normal CKMB > 3x ULN 2. < 72 hrs post PCI, baseline CKMB high CKMB > 1.5 x baseline 3. > 72 hrs post PCI Elevated Tn with symptoms or ECG changes 4. < 72 hrs post CABG CKMB > 5 x ULN and new Q waves or LBBB 5. Sudden Death Cardiac Arrest with ST elevation/LBBB and/or evidence of thrombus at autopsy/angiography

Study Definitions Prolonged Hypotension  1. Elective IABP MAP 10 mins despite fluids OR new inotropes to maintain MAP >75mmHg  2. No Planned IABP As above OR insertion of IABP to maintain MAP >75mmHg Major bleed  >4g/dl drop in Hb Minor bleed  2-4g/dl drop in Hb

Inclusion Criteria Impaired LV function (EF < 30%) Impaired LV function (EF < 30%) and and Extensive Myocardium at Risk Extensive Myocardium at Risk  BCIS-1 Jeopardy Score > 8  or...Target vessel supplying occluded vessel which supplies >40% of myocardium

Jeopardy Score Califf et al JACC 1985;5: Major Coronary Segments 2 points for each lesion + 2 for each territory distal to lesion

Jeopardy Score BCIS-1 Allows LM and Graft Classification Perera et al AHJ 2009; in press 6 Major Coronary Segments 2 points for each lesion + 2 for each territory distal to lesion Negative points for functioning grafts

Exclusion Criteria Cardiogenic Shock  Systolic BP <85 mmHg despite correction of hypovolemia Acute MI < 48 hours before randomization Planned staged PCI within 28 days Complications of acute MI  VSD, severe MR or intractable VT/VF Contraindication to IABP

BCIS-1 Recruitment Completed 21 st Jan 09 Total 301 patients

Baseline Characteristics IABP N=151 No Planned N=150 Male (%)122 (81.0)117 (78.0) Mean Age (SD)71 (9.3)71 (9.7) Diabetes (%)56 (37.1)50 (33.1) Prior MI (%)113 (74.8)108 (72.9) Prior PCI (%)17 (11.3)14 (9.3) Prior CABG (%)25 (16.6)20 (13.3) NYHA 3/4 (%)99 (66)108 (72) CCS 3/4 (%)72 (48)68 (45.5) GFR median (IQR)58.2 (45.0, 78.6)60.0 (41.9, 80.0)

Inclusion Characteristics IABP N=151 No Planned N=150 Mean E.F. (SD)23.6 (5.2) BCIS-1 Jeopardy Score Mean (SD)10.38 (1.71)10.32 (1.72) 840 (26.5%)42 (28%) 1039 (25.8%)39 (26%) 1271 (47%)68 (45.3%)

Procedural Details IABPNo Planned Elective70 (46%)65 (43%) Urgent/ Emergency81 (53%)85 (57%) Lesions attempted Lesions successfully revasc94.7%94.1% Mean lesions per patient Mean stents per patient GP2b3a use39.3%43.3%

Components of the Primary Outcome: MACCE to Hospital Discharge/ 28 days IABPNo Planned n=151(%)n=150(%) p value* Death3(2.0)1(0.7) 0.40 CVA2(1.3)0(0.0) MI19(11.3)20(13.3) 0.43 Revasc1(0.0)4(1.4) 0.13 Total † † Hierarchical 1 patient had MI and died; 2 patients had MI and PCI * Cox regression

Major Secondary Outcomes IABPNo Plannedp value 6/12 Mortality7 (4.6%)11 (7.3%) 0.32 † Procedural complication2 (1.3)16 (10.7) Access site complication5 (3.3)0 (0)0.06* All bleeds29 (19.3)17 (11.3)0.058 Major bleeds5 (3.3)6 (4.0)0.77 Minor bleeds24 (15.9)11 (7.3)0.021 Procedural success230 (93.5)237 (93.3)0.93 LOS - median days (IQR)2 (1,5)2 (1,4)0.12 †  2 test* Fisher’s exact test

Kaplan Meier 6 month mortality 7.3% vs 4.6%, p = 0.32 Elective IABPNo Planned

IABP Use IABPNo Planned IABP Inserted147 (98%)18 (12%) Reason for Insertion Randomized Allocation1470 Hypotension013 Ventricular Arrhythmia00 Pulmonary Oedema01 Vessel Closure01 Other03 Median duration of use (hrs) (IQR) (6, 23.1)(17.3, 26.4)

IABP Use in No Planned Group IABP inserted as ‘bailout’ in 18 patients (12%) hypotension in 13 (72%) Pulmonary oedema in 1, vessel closure in 1 In these patients: EF % Jeopardy Score ; JS 12 in 13 pts (72%) Duration of IABP: median of 22.9 hrs (vs 8.6 hrs in elective group) MACCE occurred in 4 patients (22%)

Conclusions BCIS have performed the first randomized trial of elective vs. ‘bailout’ IABP in patients with poor LV function and severe coronary disease We did not find evidence that Elective IABP to support high risk PCI is associated with a reduction in MACCE at hospital discharge 12% in the no-planned group required emergency IABP, supporting the important role of provisional IABP use Patients with poor LV function and severe coronary disease treated by PCI appear to have acceptable in-hospital and 6 month mortality (1.3% and 6%)

CenterPrincipal InvestigatorNumber St ThomasRedwood62 BirminghamPitt53 Brightonde Belder32 LeedsBlackman32 LiverpoolStables28 GlasgowOldroyd17 King’s CollegeThomas17 WolverhamptonCotton15 BournemouthSwallow14 BlackpoolRoberts9 LeicesterGershlick4 SouthamptonCurzen4 St GeorgesBrecker4 DorsetWitherow3 ManchesterFrazer3 NottinghamHenderson3 StokeNolan1